Aethlon Medical, Inc. (NASDAQ:AEMD) is reporting fourth quarter financial results on Thursday 25th June 2020, after market close.
According to analysts surveyed by Thomson Reuters, AEMD is expected to report 4Q20 loss of $ 0.16 per share from revenue of $ 0.30 million.
For the full year, analysts anticipate top line of $ 0.70 million, while looking forward to loss of $ 5.12 per share bottom line.
Stock Performance
According to the previous trading day, closing price of AEMD was $ 2.25, representing a 196.05 % increase from the 52 week low of $ 0.76 and a 75 % decrease over the 52 week high of $ 9.00.
The company has a market capital of $ 21.07 million and is part of the Technology sector and Scientific & Technical Instruments industry.
Conference Call
Aethlon Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 25th June 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, 1-844-836-8741 Toll Free or 1-412-317-5442 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website dpregister.com/DiamondPassRegistration/register?linkSecurityString=78449&confirmationNumber=
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection.
